keyword
MENU ▼
Read by QxMD icon Read
search

breast chemotherapy

keyword
https://www.readbyqxmd.com/read/29443653/efficacy-of-chemotherapy-for-er-negative-and-er-positive-isolated-locoregional-recurrence-of-breast-cancer-final-analysis-of-the-calor-trial
#1
Irene L Wapnir, Karen N Price, Stewart J Anderson, André Robidoux, Miguel Martín, Johan W R Nortier, Alexander H G Paterson, Mothaffar F Rimawi, István Láng, José Manuel Baena-Cañada, Beat Thürlimann, Eleftherios P Mamounas, Charles E Geyer, Shari Gelber, Alan S Coates, Richard D Gelber, Priya Rastogi, Meredith M Regan, Norman Wolmark, Stefan Aebi
Purpose Isolated locoregional recurrence (ILRR) predicts a high risk of developing breast cancer distant metastases and death. The Chemotherapy as Adjuvant for LOcally Recurrent breast cancer (CALOR) trial investigated the effectiveness of chemotherapy (CT) after local therapy for ILRR. A report at 5 years of median follow-up showed significant benefit of CT for estrogen receptor (ER)-negative ILRR, but additional follow-up was required in ER-positive ILRR. Patients and Methods CALOR was an open-label, randomized trial for patients with completely excised ILRR after unilateral breast cancer...
February 14, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29440930/advances-in-the-treatment-of-soft-tissue-sarcoma-focus-on-eribulin
#2
REVIEW
Panagiotis Koliou, Vasilios Karavasilis, Maria Theochari, Seth M Pollack, Robin L Jones, Khin Thway
Eribulin mesylate is a synthetic derivative of halichondrin B isolated from a marine sponge. Its mechanism of action is through microtubule inhibition, which is different from that of taxanes. Eribulin has been approved for the treatment of metastatic breast cancer and more recently for non-operable or metastatic liposarcoma in patients who have received prior anthracycline chemotherapy. The major side effects of eribulin are bone marrow suppression including neutropenia, leukopenia, anemia, and fatigue/weakness, which can be well managed...
2018: Cancer Management and Research
https://www.readbyqxmd.com/read/29440915/effects-of-core-needle-biopsy-and-subsequent-neoadjuvant-chemotherapy-on-molecular-alterations-and-outcome-in-breast-cancer
#3
Lingmin Xie, Xiaolei Li, Qinchuan Wang, Jichun Zhou, Jun Shen, Lixi Luo, Yi Lu, Linbo Wang
Objectives: The aim of our study is to evaluate the effect of core needle biopsy (CNB) and subsequent neoadjuvant chemotherapy (NAC) on the expression of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth hormone receptor 2 (HER2) and Ki67 in breast cancer, and the associated influencing factors. Materials and methods: In this retrospective cohort study, 143 patients with primary operable breast cancer who received NAC were included. ER, PR, HER2 and Ki67 statuses were compared between pretreatment and posttreatment residual samples...
2018: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29440897/fabrication-of-paclitaxel-hybrid-nanomicelles-to-treat-resistant-breast-cancer-via-oral-administration
#4
Ling-Hui Dian, Ying-Jie Hu, Jia-Ye Lin, Jing-Ying Zhang, Yan Yan, Yi-Nuo Cui, Zhan-Bo Su, Wan-Liang Lu
Aim: Oral chemotherapy using anticancer drugs would improve the clinical practice and the life quality of patients. The aim of the present study was to develop paclitaxel hybrid nanomicelles for oral administration to treat resistant breast cancer. Methods: Evaluations were performed on human breast cancer MCF-7 cells, drug-resistant breast cancer MCF-7/Adr cells, and in MCF-7/Adr-xenografted BALB/c nude mice. The nanomicelles were composed of the polymer soluplus, d-α-tocopheryl polyethyleneglycol 1000 succinate (TPGS 1000 ), and dequalinium (DQA)...
2018: International Journal of Nanomedicine
https://www.readbyqxmd.com/read/29440820/beware-reduced-functional-capacity-and-quality-of-life-with-increased-fatigue-level-among-the-breast-cancer-survivors-undergoing-chemotherapy-in-india
#5
S Ramachandran, Selvaraj Sudhakar, Fousiya Thaslim, S Veena Kirthika, K Padmanabhan, Asir John Samuel
No abstract text is available yet for this article.
January 2018: Indian Journal of Palliative Care
https://www.readbyqxmd.com/read/29440804/prevalence-and-severity-of-sleep-disturbances-among-patients-with-early-breast-cancer
#6
Rami Fakih, Mahmoud Rahal, Lara Hilal, Lana Hamieh, Mohammed Dany, Simone Karam, Latifa Shehab, Nagi S El Saghir, Arafat Tfayli, Ziad Salem, Hazem Assi, Sally Temraz, Ali Shamseddine, Deborah Mukherji
Context: Data regarding health-related quality of life in breast cancer patients in the Middle East are limited with fatigue and sleep disturbance being the most distressing symptoms reported by patients treated for early breast cancer. Aims: The aim of this study was to examine the prevalence and incidence of insomnia among patients with early-stage breast cancer patients treated with chemotherapy. Subjects and Methods: This was a prospective cohort study...
January 2018: Indian Journal of Palliative Care
https://www.readbyqxmd.com/read/29439778/the-importance-of-histological-assessment-after%C3%A2-neoadjuvant-therapy-and-the-need-for-standardisation
#7
REVIEW
K Naidoo, S E Pinder
Neoadjuvant therapy is increasingly being recognised as a management option for patients with primary invasive breast carcinoma; this may take the form of primary endocrine treatment or primary chemotherapy. Surgical specimens from women treated with neoadjuvant treatments, particularly primary chemotherapy, may cause a challenge for the histopathologist in handling and interpretation and have, in the past, been sampled, evaluated, and reported in a non-standardised way. This limits comparison between clinical trials and potentially provides clinicians and patients with suboptimal prognostic information...
February 10, 2018: Clinical Radiology
https://www.readbyqxmd.com/read/29439772/stomatitis-associated-with-mammalian-target-of-rapamycin-inhibition-a-review-of-pathogenesis-prevention-treatment-and-clinical-implications-for-oral-practice-in-metastatic-breast-cancer
#8
Mark S Chambers, Hope S Rugo, Jennifer K Litton, Timothy F Meiller
BACKGROUND: Patients with metastatic breast cancer may develop oral morbidities that result from therapeutic interventions. Mammalian target of rapamycin (mTOR) inhibitor-associated stomatitis (mIAS) is a common adverse event (AE), secondary to mTOR inhibitor therapy, that can have a negative impact on treatment adherence, quality of life, and health care costs. A multidisciplinary team approach is important to minimize mIAS and to maximize treatment benefits to patients with breast cancer...
February 10, 2018: Journal of the American Dental Association
https://www.readbyqxmd.com/read/29439177/real-world-impact-of-a-decision-support-tool-on-colony-stimulating-factor-use-and-chemotherapy-induced-febrile-neutropenia-among-patients-with-breast-cancer
#9
Abiy Agiro, Andrea DeVries, Jennifer Malin, Michael J Fisch
Background: White blood cell colony-stimulating factors (CSFs) decrease the incidence of chemotherapy-induced febrile neutropenia (FN). Widespread use of CSFs that is not guideline-concordant has been reported. Among patients with breast cancer receiving chemotherapy, the ability of evidence-based decision support tools to promote risk-appropriate reductions in CSF use without increased incidence of FN has not been examined. Methods: A retrospective cohort design and US commercial claims data were used. The impact of CSF decision support was analyzed among women with breast cancer receiving first-cycle chemotherapy from April 1, 2013, to March 30, 2015...
February 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/29436616/synergistic-promoting-effects-of-pentoxifylline-and-simvastatin-on-the-apoptosis-of-triple-negative-mda-mb-231-breast-cancer-cells
#10
Yessica Cristina Castellanos-Esparza, Shuang Wu, Limin Huang, Catherine Buquet, Rong Shen, Berenice Sanchez-Gonzalez, Ethel Awilda García Latorre, Olivier Boyer, Remi Varin, Luis Antonio Jiménez-Zamudio, Anne Janin, Jean-Pierre Vannier, Hong Li, He Lu
Pentoxifylline (PTX), a xanthine family molecule and simvastatin (SIM), an anti-hypercholesterolemic agent, have recently been considered as sensitizers to chemotherapy and radiotherapy. The present in vitro study evaluated their antitumor synergistic effects on MDA‑MB‑231 breast cancer cells characterized by the triple‑negative phenotype (TNP). The anti-proliferative effects of these two agents were evaluated by MTT and clonogenic assays. Cell cycle progression was examined using propidium iodide staining...
February 9, 2018: International Journal of Oncology
https://www.readbyqxmd.com/read/29436217/a-stealth-and-fully-laden-drug-carrier-self-assembled-nanogel-encapsulated-with-epigallocatechin-gallate-and-sirna-for-drug-resistant-breast-cancer-therapy
#11
Jie Ding, Tingxizi Liang, Qianhao Min, Li-Ping Jiang, Jun-Jie Zhu
For co-delivery of therapeutic genes and chemical agents in combined therapy, the ideal drug delivery system (DDS) entails high-capacity and low-body toxicity carriers, allowing adequate drug dose for tumor region while yielding low residue in normal tissue. To augment the gene/drug load capacity and circumvent the potential toxicity brought by traditional inorganic and polymeric nanocarriers, a "stealth" carrier was herein designed in a simple self-assembly of (-)-epigallocatechin-3-O-gallate (EGCG) and small interfering RNA (siRNA) by recruiting protamine as biodegradable medium for the treatment of drug-resistant triple-negative breast cancer (TNBC)...
February 13, 2018: ACS Applied Materials & Interfaces
https://www.readbyqxmd.com/read/29435853/do-patients-whose-tumor-achieved-a-pathological-response-relapse-at-specific-sites-a-substudy-of-the-eortc-10994-big-1-00-trial
#12
Kim C Aalders, Nathan Touati, Konstantinos Tryfonidis, Mylène Annonay, Saskia Litiere, Jonas Bergh, Alexandre Bodmer, David A Cameron, Hervé R Bonnefoi
PURPOSE: To determine the sites of first distant relapse in patients with or without pCR following neoadjuvant chemotherapy in breast cancer patients enrolled in the EORTC 10994/BIG-1-00 trial. METHODS: We included patients enrolled in the EORTC 10994/BIG-1-00 trial who received at least one chemotherapy cycle before surgery and who had been diagnosed with a distant relapse. pCR was defined as no evidence of residual invasive cancer in the primary tumor and axillary lymph nodes with or without residual ductal carcinoma in situ...
February 12, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29435730/bi-weekly-eribulin-therapy-for-metastatic-breast-cancer-a-multicenter-phase-ii-prospective-study-just-study
#13
Shoichiro Ohtani, Takahiro Nakayama, Tetsuhiro Yoshinami, Ken-Ichi Watanabe, Fumikata Hara, Yasuaki Sagara, Hidetoshi Kawaguchi, Kenji Higaki, Nobuki Matsunami, Yoshie Hasegawa, Masato Takahashi, Makiko Mizutani, Takashi Morimoto, Masako Sato, Mitsuya Itoh, Satoshi Morita, Norikazu Masuda
BACKGROUND: This study aimed to investigate whether schedule modification is safe and effective in patients intolerant to the standard eribulin dose and schedule. METHODS: Patients with metastatic breast cancer (MBC) treated with both anthracycline and taxane and ≤ 3 prior regimens of chemotherapy for MBC received eribulin at the standard dose and schedule (1.4 mg/m2 on days 1 and 8 of a 21-day cycle) in the first cycle; change of dosing schedule (1.4 mg/m2 on days 1 and 15 of a 28-day cycle) was determined by change in neutrophil count, platelet count, aspartate aminotransferase, alanine aminotransferase, total bilirubin, serum creatinine, and non-hematological toxicity on day 8 of the first cycle or day 1 of the second cycle...
February 12, 2018: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://www.readbyqxmd.com/read/29435713/incidence-of-infusion-hypersensitivity-reaction-after-withholding-dexamethasone-premedication-in-early-breast-cancer-patients-not-experiencing-two-previous-cycles-of-infusion-hypersensitivity-reaction-for-weekly-paclitaxel-chemotherapy
#14
Napa Parinyanitikul, Walailuk Tanpipattanakul, Nattaya Poovorawan, Thanapoom Rattananupong, Poranee Laoitthi, Piyada Sithidetphaiboon, Suebpong Thanasanvimon, Virote Sriuranpong
BACKGROUND: Premedication with dexamethasone is an essential part of the prevention of hypersensitivity reaction (HSR) associated with taxane administration. However, the possibility of stopping dexamethasone premedication has been investigated in previous studies to reduce the steroid's adverse events; however, either the result or the particular protocol was limited. Thus, our study aimed to evaluate the incidence of HSR after dexamethasone premedication discontinuation after lack of HSR in two previous weekly paclitaxel infusions...
February 12, 2018: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29434941/paclitaxel-induced-hypothermia-and-hypoperfusion-increase-breast-cancer-metastasis-and-angiogenesis-in-mice
#15
Nozomi Ami, Hideki Sato, Yoshihiro Hayakawa
Housing temperature has been shown to influence thermoregulation and behavior of preclinical cancer models; and anti-cancer drugs typically reduce peripheral blood flow and body temperature. In the present study, the effects of paclitaxel (PTX)-induced reduction of body temperature and peripheral blood flow on metastatic 4T1 breast cancer was investigated in a mouse model and the modification of these effects by thermoneutral temperature was also assessed. A single dose of PTX decreased the body temperature and peripheral blood flow in mice housed at a standard temperature (23°C)...
February 2018: Oncology Letters
https://www.readbyqxmd.com/read/29434896/intra-arterial-interventional-therapy-for-inoperable-local-advanced-breast-cancer-a-retrospective-study
#16
Jing Ma, Jin Song, Hai Chen, Cibo Fan, Jiaqi Xie, Xiaodong Qi
The aim of the present study was to evaluate the safety and efficacy of intra-arterial interventional therapy (IAIT) in the treatment of inoperable local advanced breast cancer (LABC). A total of 7 patients with pathologically proven inoperable LABC were included in the present study. Patients received 1-4 cycles of IAIT prior to mastectomy and postoperative adjuvant therapy. The safety and clinical outcomes of IAIT were retrospectively analyzed. Between February 2009 to September 2016, 7 patients received IAIT...
February 2018: Oncology Letters
https://www.readbyqxmd.com/read/29434858/mir-125b-regulates-the-drug-resistance-of-breast-cancer-cells-to-doxorubicin-by-targeting-hax-1
#17
Guinv Hu, Xiaokang Zhao, Jiang Wang, Liting Lv, Chaoqun Wang, Liang Feng, Liangqiong Shen, Weili Ren
MircroRNAs (miRNAs) are considered as essential regulators in the tumorigenesis and chemoresistance of multiple cancer types. In the present study, it was demonstrated that the expression levels of miR-125b were significantly downregulated in the tissues of patients with breast cancer (BC), as well as the BC cell lines in vitro. To study the association between chemoresistance and miR-125b in BC, doxorubicin (DOX)-resistant MCF-7 (MCF-7/R) cells were established, and gain- and loss-of-function experiments were performed...
February 2018: Oncology Letters
https://www.readbyqxmd.com/read/29434836/increased-expression-of-mitochondrial-transcription-factor-a-and-nuclear-respiratory-factor-1-predicts-a-poor-clinical-outcome-of-breast-cancer
#18
Wei Gao, Meihong Wu, Ning Wang, Yingyi Zhang, Jing Hua, Gusheng Tang, Yajie Wang
Nuclear respiratory factor-1 (Nrf1) and mitochondrial transcription factor A (TFAM) are involved in the regulation of a variety of mitochondrial functional genes, which are associated with decreased sensitivity of tumor cells to chemotherapy. However, the expression status of Nrf1 and TFAM, as well as their clinical significance in breast cancer, is unknown. In the present study, tumor tissues and corresponding adjacent normal tissues were collected from 336 patients with breast cancer, and Nrf1 and TFAM expression was analyzed by immunohistochemistry using a tissue microarray...
February 2018: Oncology Letters
https://www.readbyqxmd.com/read/29433963/pertuzumab-and-trastuzumab-with-or-without-metronomic-chemotherapy-for-older-patients-with-her2-positive-metastatic-breast-cancer-eortc-75111-10114-an-open-label-randomised-phase-2-trial-from-the-elderly-task-force-breast-cancer-group
#19
Hans Wildiers, Konstantinos Tryfonidis, Lissandra Dal Lago, Peter Vuylsteke, Giuseppe Curigliano, Simon Waters, Barbara Brouwers, Sevilay Altintas, Nathan Touati, Fatima Cardoso, Etienne Brain
BACKGROUND: Despite the high incidence of metastatic breast cancer and its related mortality in the elderly population, our knowledge about optimal treatment for older patients with cancer is far from adequate. We aimed to evaluate the efficacy of dual anti-HER2 treatment with or without metronomic chemotherapy in older patients with HER2-positive metastatic breast cancer. METHODS: We did a multicentre, open-label, randomised, phase 2 trial in 30 centres from eight countries in Europe, in patients with histologically proven, HER2-positive metastatic breast cancer, without previous chemotherapy for metastatic disease, who were 70 years or older, or 60 years or older with confirmed functional restrictions defined by protocol, and had a life expectancy of more than 12 weeks and a performance status according to WHO scale of 0-3...
February 9, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29433753/a-glutathione-responsive-sulfur-dioxide-polymer-prodrug-as-a-nanocarrier-for-combating-drug-resistance-in-cancer-chemotherapy
#20
Wei Shen, Wanguo Liu, Huailin Yang, Peng Zhang, Chunsheng Xiao, Xuesi Chen
Multidrug resistance (MDR) in cancer remains a significant challenge for curing cancer by chemotherapy. In this work, a kind of glutathione (GSH)-responsive polymer prodrug of SO2 was designed and synthesized, which presented synergistic effect with doxorubicin (DOX) for combating MCF-7 ADR human breast cancer cell. Firstly, a small molecular prodrug of SO2, N-(3-azidopropyl)-2,4-dinitrobenzenesulfonamide (AP-DNs), was chemically conjugated onto the side chain of methoxy poly (ethylene glycol)-block-poly (γ-propargyl-l-glutamate) (mPEG-PPLG) block copolymer to generate an amphiphilic polymer prodrug of SO2, mPEG-PLG (DNs)...
February 3, 2018: Biomaterials
keyword
keyword
82103
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"